Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: SMALL FRY who wrote (76445)	12/23/1999 10:43:00 AM
From: Jenna	Read Replies (3) \| Respond to of 120523

For the Biotech: I'm back in CELG hoping it will make a splash, and SUPG now SHPGY (Shire) and Roberts (RPC) Merger Completed New Shire Shares Commence Trading Today ANDOVER, England, Dec. 23 /PRNewswire/ -- Shire Pharmaceuticals Group plc (Nasdaq: SHPGY; LSE: SHP.L) announces the completion of the merger with Roberts Pharmaceutical Corporation (Roberts) (Amex: RPC - news) following shareholder approval from both companies yesterday. Shire Pharmaceuticals Group plc (Shire), following the merger, has a market capitalisation of 1,505 million Pounds Sterling ($2,423 million) based on yesterday's London closing price (615.5p) and the enlarged issued share capital of 244,508,268 ordinary shares. The listing of Roberts' common stock on the American Stock Exchange has been cancelled. The 100,767,482 new Shire ordinary shares are expected to be admitted to the Official List of the London Stock Exchange and commence trading on London Stock Exchange and Nasdaq at 2:30 p.m. GMT (9:30 a.m. US ET) today. Shire intends to become a significant, international pharmaceutical company through the development, licensing and marketing of prescription medicines advancing the treatment of bone diseases and central nervous system disorders. The principal activities of the group are the marketing, licensing and development of prescription medicines. The group focuses on the prevention and treatment of osteoporosis and other matabolic bone diseases and the treatment of selected disorders of the central nervous system, particularly Alzheimer's desease. RPC was always a good play and I'm seeing that SHPGY is up day after day. Now I've got TEVA which is a very famous Israeli Pharmaceutical company